NTLA - Intellia Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Intellia Therapeutics, Inc.

40 Erie Street
Suite 130
Cambridge, MA 02139
United States

Full Time Employees195

Key Executives

NameTitlePayExercisedYear Born
Dr. John M. LeonardPres, CEO & Director568.58kN/A1957
Mr. Nessan Bermingham Ph.D.Founder & Member of Scientific Advisor Board1.38MN/A1973
Mr. José E. RiveraExec. VP & Gen. Counsel618.51kN/A1966
Ms. Rachel Haurwitz Ph.D.Co-FounderN/AN/A1986
Mr. Andrew May Ph.D.Founder and Member of Scientific Advisor BoardN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Intellia Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2018 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.